Disease · MONDO_0018044
idiopathic hypersomnia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. idiopathic hypersomnia. Diseases, record MONDO_0018044. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018044
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PITOLISANT | CHEMBL462605 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SODIUM OXYBATE | CHEMBL1200682 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| OXYBATE | CHEMBL1342 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CLARITHROMYCIN | CHEMBL1741 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AMPHETAMINE/DEXTROAMPHETAMINE | CHEMBL5095505 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MELATONIN | CHEMBL45 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MODAFINIL | CHEMBL1373 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SERDEXMETHYLPHENIDATE | CHEMBL4301162 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SOLRIAMFETOL | CHEMBL4297620 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DANAVOREXTON | CHEMBL4650341 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets7
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GABBR1 | GABA-B receptor | 2 | GABA-B receptor agonist | Phase 3 | https://conductscience.org/library/genes/2550 | Drugs and targets |
| GABBR2 | GABA-B receptor | 2 | GABA-B receptor agonist | Phase 3 | https://conductscience.org/library/genes/9568 | Drugs and targets |
| SLC6A3 | Sodium-dependent dopamine transporter | 2 | Dopamine transporter inhibitor | Phase 2 | https://conductscience.org/library/genes/6531 | Drugs and targets |
| HRH3 | Histamine H3 receptor | 1 | Histamine H3 receptor inverse agonist | Phase 3 | https://conductscience.org/library/genes/11255 | Drugs and targets |
| MTNR1A | Melatonin receptor | 1 | Melatonin receptor agonist | Phase 2 | https://conductscience.org/library/genes/4543 | Drugs and targets |
| MTNR1B | Melatonin receptor | 1 | Melatonin receptor agonist | Phase 2 | https://conductscience.org/library/genes/4544 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 1 | Norepinephrine transporter inhibitor | Phase 2 | https://conductscience.org/library/genes/6530 | Drugs and targets |
Trials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03533114 | A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension | Phase 3 | 154 | 2021-11-24 | Idiopathic Hypersomnia | OXYBATE | Its record names the disease | ClinicalTrials.gov |
| NCT03772314 | Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia | Phase 2 | 44 | 2024-05-23 | Idiopathic Hypersomnia, Narcolepsy Without Cataplexy | AMPHETAMINE/DEXTROAMPHETAMINE, MODAFINIL | Its record names the disease | ClinicalTrials.gov |
| NCT04091438 | A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia | Phase 1 | 28 | 2023-09-26 | Idiopathic Hypersomnia | DANAVOREXTON | Its record names the disease | ClinicalTrials.gov |
| NCT01146600 | Clarithromycin for the Treatment of Hypersomnia | Phase 2 | 26 | 2014-06-12 | Hypersomnia, Idiopathic Hypersomnia, Narcolepsy | CLARITHROMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT05156047 | A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia | Phase 3 | 214 | Idiopathic Hypersomnia | PITOLISANT | Its record names the disease | ClinicalTrials.gov | |
| NCT06525077 | Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ) | Phase 3 | 157 | Idiopathic Hypersomnia | SODIUM OXYBATE | Its record names the disease | ClinicalTrials.gov | |
| NCT05458128 | A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia | Phase 3 | 119 | Idiopathic Hypersomnia, Excessive Daytime Sleepiness | PITOLISANT | Its record names the disease | ClinicalTrials.gov | |
| NCT04026958 | Clarithromycin Mechanisms in Hypersomnia Syndromes | Phase 2 | 83 | Narcolepsy Without Cataplexy, Idiopathic Hypersomnia, Narcolepsy With Cataplexy | CLARITHROMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06252571 | a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial | Phase 2 | 72 | Idiopathic Hypersomnia | MELATONIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05668754 | Study of SDX in Patients With Idiopathic Hypersomnia (IH) | Phase 2 | 66 | Idiopathic Hypersomnia | SERDEXMETHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| JZP-258 vs Placebo: Percentage of Participants Reported as Worse on the Patient Global Impression of Change (PGIc) | 12 of 56 | 52 of 59 | 115 | NCT03533114 | Trial comparisons |
| JZP-258 vs Placebo: Percentage of Participants Reported as Worse on the Clinical Global Impression of Change (CGIc) | 12 of 56 | 52 of 59 | 115 | NCT03533114 | Trial comparisons |
| TAK-925 112 mg vs Placebo: deaths from any cause | 0 of 25 | 0 of 27 | 52 | NCT04091438 | Trial comparisons |
| TAK-925 112 mg vs Placebo: serious adverse events | 0 of 25 | 0 of 27 | 52 | NCT04091438 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: deaths from any cause | 0 of 22 | 0 of 22 | 44 | NCT03772314 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: serious adverse events | 1 of 22 | 0 of 22 | 44 | NCT03772314 | Trial comparisons |
| Clarithromycin vs Placebo: serious adverse events | 0 of 22 | 0 of 20 | 42 | NCT01146600 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: Number of Participants Reporting Much or Very Much Improvement From Baseline on Patient Global Impression of Change (PGIC) for Sleepiness Score | 14 of 22 | 10 of 20 | 42 | NCT03772314 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: Number of Participants Reporting Much or Very Much Improvement by Patient Global Impression of Change (PGIC) for Overall Disease Severity Score | 13 of 22 | 10 of 20 | 42 | NCT03772314 | Trial comparisons |
| Modafinil vs Amphetamine-dextroamphetamine: Number of Participants Reporting Much or Very Much Improvement With Patient Global Impression of Change (PGIC) for Cognitive Dysfunction Score | 5 of 22 | 10 of 20 | 42 | NCT03772314 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials10
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018044
GET https://conductscience.org/api/diseases/v1/MONDO_0018044/drugs